← All agents | ← Research tracker
Fluvoxamine
PubChem entry
Evidence Summary
Evidence Level: Moderate
Mechanism: Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other
Safety: Nausea, insomnia, somnolence; significant CYP1A2 and CYP2C19 interactions. Avoid in combination with thioridazine, pimozide. Monitor for serotonin syndrome if combined with other serotonergics.
Dosing: 50–100 mg/day (often 100 mg); short courses (10–15 days) in early studies; some PASC protocols 4–8 weeks.
Sigma-1 + SSRI; early COVID + some Long COVID data. 50-100mg. CYP interactions, GI/insomnia. Preliminary for select symptoms; not core fatigue/autonomic first choice.
Related Conditions
Long COVID (no page yet) · ME/CFS (no page yet)
Clinical Trials
4 trial(s) registered
NCT05874037: Fluvoxamine for Long COVID-19 PHASE2 COMPLETED
NCT07359482: sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 PHASE3 RECRUITING
NCT04510194: COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) PHASE3 COMPLETED
NCT06128967: A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial PHASE3 COMPLETED
Key Studies / References